Harness Therapeutics wins grant to develop disease-modifying Parkinson’s drug (opens in new tab)

Harness Therapeutics has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research through the Parkinson’s Disease Therapeutics Pipeline Program to advance a two-year programme targeting glucocerebrosidase (GCase) and lysosomal integral membrane protein-2 (LIMP2) in GBA1-associated Parkinson’s disease. The programme will leverage Harness’s proprietary MISBA microRNA steric blocking ASO platform to pursue […] The post appeared first on <a href="